What does CUSIP 21077P108 represent in this 13F holders report?

CUSIP 21077P108 is the security identifier for CNTX - Context Therapeutics Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held CNTX - Context Therapeutics Inc. - Common Stock in Q1 2026?

59 institutional investors reported CNTX - Context Therapeutics Inc. - Common Stock for Q1 2026. Use the holders table for investor-level position and value details.

Context Therapeutics Inc. - Common Stock (CNTX)

CUSIP: 21077P108

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock
Shares outstanding: 91,741,639
Total 13F shares: 74,175,436
Share change: +8,978,356
Total reported value: $193,038,472
Put/Call ratio: 203%
Price per share: $2.62
Number of holders: 59
Value change: +$28,758,977
Number of buys: 32
Number of sells: 20

Quarterly Holders Quick Answers

What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 21077P108:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Avidity Partners Management LP	13D/G 13F	Company	8.7%	8,302,808	$21,753,357	-$2,352,163	31 Mar 2026	13D/G 13F
Soleus Capital Master Fund, L.P.	13D/G	—	7.6%	6,963,141	$18,243,429	+$5,729,267	31 Mar 2026	13D/G
MPM BioImpact LLC	13F 13D/G	Company	12% from 13D/G	10,679,391	$15,698,705	—	31 Dec 2025	13F 13D/G
Octagon Capital Advisors LP	13D/G	—	5.7%	5,250,000	$13,755,000	$0	31 Mar 2026	13D/G
Blue Owl Capital Holdings LP	13D/G 13F	Company	5.5%	5,089,015	$13,333,219	-$3,324,552	31 Mar 2026	13D/G 13F
Deep Track Capital, LP	13F 13D/G	Company	8.3% from 13D/G	7,419,355	$10,906,452	—	31 Dec 2025	13F 13D/G
Nextech Invest, Ltd.	13F	Company	8.1%	7,419,355	$10,906,452	—	31 Dec 2025	13F
GREAT POINT PARTNERS LLC	13F 13D/G	Company	2.4% from 13D/G	4,683,711	$6,885,055	—	31 Dec 2025	13F 13D/G
FRANKLIN RESOURCES INC	13F 13D/G	Company	4.5% from 13D/G	4,003,380	$5,884,969	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	4.1%	3,785,909	$5,565,287	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	2.8%	2,601,216	$3,823,788	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	2.8%	2,593,198	$3,812,001	—	31 Dec 2025	13F
Blackstone Inc.	13F	Company	2.7%	2,440,330	$3,587,285	—	31 Dec 2025	13F
Alyeska Investment Group, L.P.	13F	Company	1.8%	1,663,355	$2,445,132	—	31 Dec 2025	13F
Sio Capital Management, LLC	13F	Company	1.5%	1,341,636	$1,972,205	—	31 Dec 2025	13F
Martin A. Lehr	13D/G 3/4/5	Martin Lehr · Chief Executive Officer, Director	2.1%	1,595,742	$1,595,742	$0	31 Dec 2024	13D/G 3/4/5
BlackRock, Inc.	13F	Company	0.92%	848,046	$1,246,628	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.66%	608,462	$894,882	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.55%	508,329	$747,244	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.38%	351,094	$516,108	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.18%	165,607	$243,442	—	31 Dec 2025	13F
Walleye Capital LLC	13F	Company	0.14%	132,786	$195,195	—	31 Dec 2025	13F
HighTower Advisors, LLC	13F	Company	0.14%	125,852	$185,002	—	31 Dec 2025	13F
Pathstone Holdings, LLC	13F	Company	0.12%	110,244	$162,059	—	31 Dec 2025	13F
Mill Creek Capital Advisors, LLC	13F	Company	0.11%	104,631	$153,808	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.11%	101,605	$149,359	—	31 Dec 2025	13F
Velan Capital Investment Management LP	13F	Company	0.11%	100,000	$147,000	—	31 Dec 2025	13F
Clear Harbor Asset Management, LLC	13F	Company	0.1%	92,804	$136,422	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.09%	84,281	$123,893	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.06%	52,701	$77,470	—	31 Dec 2025	13F
Quadrature Capital Ltd	13F	Company	0.05%	46,220	$67,943	—	31 Dec 2025	13F
Alex C. Levit	3/4/5	Chief Legal Officer, Corp. Sec	— mixed-class rows	351,983 mixed-class rows	$58,030	+$11,520	19 Feb 2026	3/4/5
Nantahala Capital Management, LLC	13F	Company	0.04%	37,837	$55,620	—	31 Dec 2025	13F
Lynn Minai Azary	3/4/5	Chief Financial Officer	— mixed-class rows	355,010 mixed-class rows	$50,966	+$25,486	19 Feb 2026	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.04%	34,380	$50,539	—	31 Dec 2025	13F
Virtu Financial LLC	13F	Company	0.03%	28,921	$43,000	—	31 Dec 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.03%	25,500	$37,485	—	31 Dec 2025	13F
Cerity Partners LLC	13F	Company	0.02%	20,000	$29,400	—	31 Dec 2025	13F
CAXTON CORP	13F	Company	0.02%	18,403	$27,053	—	31 Dec 2025	13F
Corient Private Wealth LLC	13F	Company	0.02%	15,084	$22,173	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	9,611	$14,128	—	31 Dec 2025	13F
Tarek Sahmoud	3/4/5	Chief Medical Officer	— mixed-class rows	35,000 mixed-class rows	$8,415	—	16 Aug 2022	3/4/5
Strive Financial Group ,LLC	13F	Company	0%	1,700	$2,499	—	31 Dec 2025	13F
Farther Finance Advisors, LLC	13F	Company	0%	1,500	$2,205	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0%	1,348	$1,982	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	933	$1,371	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0%	490	$720	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	114	$168	—	31 Dec 2025	13F
Karen Deborah Chagin	3/4/5	Chief Medical Officer	— class O/S missing	290,000	—	—	19 Feb 2026	3/4/5
Ullmann Claudio Dansky	3/4/5	Chief Medical Officer	— class O/S missing	174,960	—	—	13 Feb 2025	3/4/5

Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q1 2026

As of 31 Mar 2026, Context Therapeutics Inc. - Common Stock (CNTX) was held by 59 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 74,175,436 shares. The largest 10 holders included MPM BIOIMPACT LLC, Nextech Invest, Ltd., Deep Track Capital, LP, Soleus Capital Management, L.P., Octagon Capital Advisors LP, Blue Owl Capital Holdings LP, Avidity Partners Management LP, FRANKLIN RESOURCES INC, VANGUARD CAPITAL MANAGEMENT LLC, and MARSHALL WACE, LLP. This page lists 59 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.